Calibration of a Non-invasive Glucose Measurement Device and Assessment of Its Performance in the Hypoglycemic Range in Patients With Type 1 Diabetes

Calibration of a Non-invasive Glucose Measurement Device and Assessment of Its Performance in the Hypoglycemic Range in Patients With Type 1 Diabetes

Sponsors

Lead Sponsor: RSP Systems A/S

Collaborator: Steno Diabetes Center Copenhagen

Source RSP Systems A/S
Brief Summary

This clinical study has been launched to collect spectral Raman data and reference measurements to establish and validate a calibration model for the device during daily glycemic fluctuations and evaluate analytical performance of device in the hypoglycemic range. The study is a combined home-based and in-clinic study where subjects will attend the clinic two times.

Overall Status Recruiting
Start Date July 1, 2019
Completion Date June 1, 2020
Primary Completion Date June 1, 2020
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Generation of predictive algorithms for determining blood glucose levels 12 months
Validation of predictive algorithms for determining blood glucose levels 12 months
Secondary Outcome
Measure Time Frame
Risk/benefit analysis 12 months
Number of encountered Device Deficiencies 12 months
Enrollment 15
Condition
Intervention

Intervention Type: Device

Intervention Name: P0.3

Description: Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.

Arm Group Label: Protocol 1

Eligibility

Criteria:

Inclusion Criteria:

- Male and female subjects between 18 and 40 years of age.

- Diagnosed with type 1 diabetes mellitus.

- Uses an insulin pen or pump.

- Hb1Ac > 55 mmol/mol at baseline visit.

- Skin phototype 1-4 according to Fitzpatrick skin tone scale.

- Willing to perform a minimum of 8 finger sticks per day during the study for the home-based study and approximately 16 finger sticks for the in-clinic study days.

- Willing to have a peripheral venous catheter inserted.

- Willing to provide written signed and dated informed consent.

Exclusion Criteria:

- Breastfeeding, pregnant, attempting to conceive or not willing and able to practice birth control according to approved contraceptives from NCA during the study execution (applicable to female subjects only).

- Subjects not able to understand and read Danish.

- Inability to comply with the study procedures as described by the study protocol, according to the opinion of the investigator.

- Subject is not able to hold hand/arm steadily (including tremors and Parkinson's Disease).

- Reduced circulation in hand. "Allen's test" is used for assessing hand circulation to evaluate occurrence of reduced blood.

- Extensive skin changes, tattoos or diseases on probe application site (thenar) that could interfere with the accuracy of the interstitial glucose measurements.

- Known allergy to medical grade alcohol.

- Having active cancer treatment and/or use tetracyclines and other medication / topical agents known to increase photosensitivity in skin.

- Medical history or any condition that may, in the opinion of the Investigator, compromise the subject's ability to participate

- Concomitant medical condition which could present a risk to the safety or welfare of the subject or study staff.

- Diagnosed with cardiovascular diseases.

- Subjects currently enrolled in another study.

- Radiotherapy for the past six months.

Gender: All

Minimum Age: 18 Years

Maximum Age: 40 Years

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Kirsten Nørgaard Principal Investigator Steno Diabetes Center Copenhagen
Overall Contact

Last Name: Stefan Ovesen Banke

Phone: +45 71 99 79 77

Email: [email protected]

Location
Facility: Status: Contact: Steno Diabetes Center Copenhagen (SDCC) Kirsten Nørgaard +45 27 13 10 11 [email protected]
Location Countries

Denmark

Verification Date

March 2020

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Protocol 1

Type: Experimental

Description: The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.

Patient Data No
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Device Feasibility

Masking: None (Open Label)

Source: ClinicalTrials.gov